Puma Biotechnology, Inc. (PBYI)
10.22
+0.39
(+3.97%)
USD |
NASDAQ |
Oct 19, 16:00
10.22
0.00 (0.00%)
After-Hours: 20:00
Puma Biotechnology EPS Diluted (Quarterly) : 0.1557 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.1557 |
| March 31, 2026 | -0.0738 |
| December 31, 2025 | 0.2608 |
| September 30, 2025 | 0.1736 |
| June 30, 2025 | 0.1168 |
| March 31, 2025 | 0.0596 |
| December 31, 2024 | 0.3907 |
| September 30, 2024 | 0.4132 |
| June 30, 2024 | -0.0938 |
| March 31, 2024 | -0.0999 |
| December 31, 2023 | 0.2554 |
| September 30, 2023 | 0.1212 |
| June 30, 2023 | 0.045 |
| March 31, 2023 | 0.0297 |
| December 31, 2022 | -0.1224 |
| September 30, 2022 | -0.0079 |
| June 30, 2022 | 0.2066 |
| March 31, 2022 | -0.0806 |
| December 31, 2021 | 0.1029 |
| September 30, 2021 | -1.094 |
| June 30, 2021 | -0.1261 |
| March 31, 2021 | 0.4042 |
| December 31, 2020 | -0.3761 |
| September 30, 2020 | -0.7926 |
| June 30, 2020 | 0.0849 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.431 |
| December 31, 2019 | -0.2869 |
| September 30, 2019 | -0.4341 |
| June 30, 2019 | -0.9683 |
| March 31, 2019 | -0.2621 |
| December 31, 2018 | -0.8036 |
| September 30, 2018 | -0.3733 |
| June 30, 2018 | -1.172 |
| March 31, 2018 | -0.6458 |
| December 31, 2017 | -1.71 |
| September 30, 2017 | -2.07 |
| June 30, 2017 | -2.10 |
| March 31, 2017 | -1.973 |
| December 31, 2016 | -2.04 |
| September 30, 2016 | -2.02 |
| June 30, 2016 | -2.05 |
| March 31, 2016 | -2.19 |
| December 31, 2015 | -1.90 |
| September 30, 2015 | -1.87 |
| June 30, 2015 | -2.01 |
| March 31, 2015 | -1.66 |
| December 31, 2014 | -1.57 |
| September 30, 2014 | -1.19 |
| June 30, 2014 | -1.29 |
| March 31, 2014 | -0.67 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Anika Therapeutics, Inc. | 0.2412 |
| Arcutis Biotherapeutics, Inc. | 0.1104 |
| Olema Pharmaceuticals, Inc. | -0.605 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 8.189M |
| Revenue (Quarterly) | 56.50M |
| Total Expenses (Quarterly) | 48.31M |
| Enterprise Value | 413.25M |
| Gross Profit Margin (Quarterly) | 77.92% |
| Profit Margin (Quarterly) | 14.49% |
| Earnings Yield | 5.05% |
| Operating Earnings Yield | 5.79% |
| Normalized Earnings Yield | 5.053 |